Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
6 February 2007 | Volume 146 Issue 3 | Page 230
We appreciate Dr. Hellman's interest and comments. We, too, have noted that nearly half of our patients with nephrogenic fibrosing dermopathy had gadolinium exposure before the development of their disease. However, a similar number of our 50 dialysis patients were also exposed to gadoliniumsome exposed on several occasionswithout any evidence of the condition. This seems to support our hypothesis that multiple factors are involved in the pathogenesis of nephrogenic fibrosing dermopathy. We are currently investigating the possible interaction between gadolinium and erythropoietin in this disease.
Potential Financial Conflicts of Interest: None disclosed.
REPLY
Erythropoietin, Gadolinium, and Nephrogenic Fibrosing Dermopathy
IN RESPONSE:
Author and Article Information
![]()
Top
Author & Article Info
From Mayo Clinic College of Medicine, Rochester, Minnesota.
Related articles in Annals:
This article has been cited by other articles:
![]() |
S. Jimenez-Valero, R. Moreno, A. Sanchez-Recalde, G. Galeote, L. Calvo, A. Viana, E. Lopez de Sa, and J. Lopez-Sendon Review: Avoiding restenosis: is there a role for glucocorticoids in the drug-eluting stent era? Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 137 - 146. [Abstract] [PDF] |
||||
![]() |
H. Pieringer, S. Schumacher, B. Schmekal, T. Gitter, and G. Biesenbach Gadolinium-based contrast agents, erythropoietin and nephrogenic systemic fibrosis in patients with end-stage renal failure NDT Plus, June 1, 2008; 1(3): 193 - 194. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||